业内人士指出，美国药品降价行动能否落地存不确定性。美国药品费用支出中商业医疗保险占比大，其高消费刺激医药创新，美国医药产业研发 技术领先全球，新药带来的利润吸引资本投入，形成良性循环，是经济增长重要动力。截至2019年底，美国约2亿人参加商业医保，覆盖率 59.1%，赔付支出占国民健康支出33.3%。 医疗战略咨询公司Latitude Health创始人赵衡称，美国法律禁止政府和药企直接谈判，仅IRA开了口子，且每年谈判药品数量有限，政策工具缺乏 影响实施。中国医药国际合作研究人士认为，特朗普此举虽维持行事风格，但落实有变数，不过利于拉近与选民距离，履行竞选承诺。此次降价 行动依据《平价医疗法案》，但因医药费用支出主要由商保支付，或招致制药和商保公司法律反诉，前景不乐观。（陈十一） 美国是全球最大医药市场，药品定价机制允许创新药依临床价值定高价。特朗普认为，即便考虑现有折扣，美国品牌药价格仍是其他国家3倍以 上，且美国人口不足全球5%，却承担约75%的全球药品利润。 中国多家创新药企产品已实现在美上市，如百济神州、君实生物等。百济神州一半以上收入源于美国市场，其BTK抑制剂百悦泽美国售价约是中 国的16倍；君 ...

Core Viewpoint - The article discusses the implications of President Trump's executive order aimed at reducing prescription drug prices in the U.S., aligning with international pricing standards, and the potential impact on the global biopharmaceutical industry [1][2]. Group 1: Impact on the Pharmaceutical Industry - The U.S. is the largest pharmaceutical market, with brand drug prices being over three times higher than those in other countries, despite existing discounts [3]. - U.S. consumers represent less than 5% of the global population but account for approximately 75% of global pharmaceutical profits [3]. - Several Chinese innovative drugs have been launched in the U.S. market, with companies like BeiGene deriving over half of their revenue from the U.S. [3]. - For instance, BeiGene's BTK inhibitor is priced at $12,935 for a 30-day treatment in the U.S., which is about 16 times the price in China [3]. - Similarly, Junshi Biosciences' PD-1 drug costs $110,600 annually in the U.S., nearly 34 times the price in China [4]. - If U.S. drug prices are lowered, it could significantly shrink the market size for innovative drugs globally, as lower prices in the U.S. would likely lead to lower prices elsewhere [4]. Group 2: Feasibility of Implementation - There is uncertainty regarding the actual implementation of the drug price reduction policy, as a significant portion of U.S. drug costs is covered by commercial health insurance [6]. - As of the end of 2019, approximately 200 million people were enrolled in commercial health insurance, covering 59.1% of the population, with commercial insurance accounting for $1.2 trillion in healthcare spending [6]. - The executive order faces legal challenges, as U.S. law prohibits direct negotiations between the government and pharmaceutical companies, limiting the effectiveness of the proposed measures [7]. - The Inflation Reduction Act (IRA) allows for some negotiation but only applies to a limited number of drugs each year, which may not be sufficient to drive significant price reductions [7]. - The announcement serves to address public concerns and reinforce Trump's political base, but the actual outcomes remain uncertain and may lead to legal disputes with pharmaceutical companies [7].

Core Viewpoint - The recent executive order signed by President Trump aims to lower prescription drug prices in the U.S. to align with international pricing, but the feasibility and specific price reductions remain uncertain [1][5][6] Group 1: Drug Pricing and Market Dynamics - The U.S. brand drug prices are over three times higher than those in other countries, despite existing discounts [2] - The U.S. accounts for approximately 75% of global pharmaceutical profits while representing less than 5% of the world's population [2] - The high drug prices in the U.S. are attributed to the healthcare system's labor costs and pricing mechanisms, with profits primarily benefiting domestic pharmaceutical companies and insurance providers [2] Group 2: Impact on Global Pharmaceutical Industry - If the U.S. drug pricing policy is implemented, it could significantly impact the global innovative drug industry [3] - Chinese companies like BeiGene and Junshi Biosciences have successfully launched innovative drugs in the U.S., with prices significantly higher than in China, indicating a potential market shift if U.S. prices are lowered [2][3] Group 3: Uncertainty of Implementation - The executive order's effectiveness is uncertain due to the U.S. legal framework that restricts direct negotiations between the government and pharmaceutical companies [6] - The current system relies on Pharmacy Benefit Managers (PBMs) for drug price negotiations, which complicates the implementation of price reductions [6] - The potential for legal challenges from pharmaceutical companies and insurers could hinder the success of the proposed pricing reforms [6]